Dr. Helen McTaggart-Cowan, PhD

AYAs with HMs have treatment plans and side effects that interrupt typical developmental processes. These barriers may impact their mental well-being and their overall quality of life.

Many AYAs with breast cancer may struggle to find the information and support they need. These challenges can be even greater for AYAs who face extra barriers because of unfair social conditions.

HRD testing is an effective biomarker test for the treatment management for advanced ovarian cancer. Currently, HRD testing is not funded publicly for all individuals in Canada.